JP2011507888A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507888A5
JP2011507888A5 JP2010539814A JP2010539814A JP2011507888A5 JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5 JP 2010539814 A JP2010539814 A JP 2010539814A JP 2010539814 A JP2010539814 A JP 2010539814A JP 2011507888 A5 JP2011507888 A5 JP 2011507888A5
Authority
JP
Japan
Prior art keywords
compound
imidazo
phenylamino
pyridine
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010539814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507888A (ja
JP5710268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/087476 external-priority patent/WO2009085980A1/en
Publication of JP2011507888A publication Critical patent/JP2011507888A/ja
Publication of JP2011507888A5 publication Critical patent/JP2011507888A5/ja
Application granted granted Critical
Publication of JP5710268B2 publication Critical patent/JP5710268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010539814A 2007-12-19 2008-12-18 ８−アニリノイミダゾピリジン及びその抗ガン及び／又は抗炎症剤としての使用 Expired - Fee Related JP5710268B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1515507P 2007-12-19 2007-12-19
US61/015,155 2007-12-19
US5402408P 2008-05-16 2008-05-16
US61/054,024 2008-05-16
PCT/US2008/087476 WO2009085980A1 (en) 2007-12-19 2008-12-18 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents

Publications (3)

Publication Number Publication Date
JP2011507888A JP2011507888A (ja) 2011-03-10
JP2011507888A5 true JP2011507888A5 (enExample) 2012-02-23
JP5710268B2 JP5710268B2 (ja) 2015-04-30

Family

ID=40404998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539814A Expired - Fee Related JP5710268B2 (ja) 2007-12-19 2008-12-18 ８−アニリノイミダゾピリジン及びその抗ガン及び／又は抗炎症剤としての使用

Country Status (16)

Country Link
US (1) US8293763B2 (enExample)
EP (1) EP2231662B1 (enExample)
JP (1) JP5710268B2 (enExample)
KR (1) KR20100101666A (enExample)
CN (1) CN101903387B (enExample)
AT (1) ATE513832T1 (enExample)
AU (1) AU2008343062B2 (enExample)
CA (1) CA2704125A1 (enExample)
DK (1) DK2231662T3 (enExample)
IL (1) IL205490A (enExample)
NZ (1) NZ585306A (enExample)
PL (1) PL2231662T3 (enExample)
PT (1) PT2231662E (enExample)
RU (1) RU2498985C2 (enExample)
WO (1) WO2009085980A1 (enExample)
ZA (1) ZA201003046B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2706571C (en) * 2007-12-19 2012-11-27 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
ES2785475T3 (es) 2011-05-10 2020-10-07 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores de canales iónicos
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
DK2755483T3 (en) 2011-09-14 2019-03-11 Samumed Llc INDAZOL-3-CARBOXAMIDES AND ITS USE AS WNT / B-CATENIN SIGNAL INHIBITORS
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
KR101223245B1 (ko) * 2012-09-12 2013-01-17 삼부기술 주식회사 영상이미지의 기준점 대비 도화하기 위한 대상 지형지물을 촬영하는 공간 영상도화 시스템
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3777956B1 (en) 2013-10-15 2024-06-12 Radux Devices, LLC Securing a medical device to a valve instrument
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
CN108358939A (zh) * 2014-07-29 2018-08-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
KR20180080262A (ko) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 골관절염의 치료
AU2017249229A1 (en) 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
MX387322B (es) 2016-04-22 2025-03-18 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
SMT202200486T1 (it) 2016-06-01 2023-01-13 Biosplice Therapeutics Inc Processo per la preparazione di n-(5-(3-(7-(3- fluorofen il)-3h-imidaz0[4,5-c]piridin-2-il)-1h-indazol-5- il)piridin-3-il)-3-metilbutanammide
KR102593742B1 (ko) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
WO2019051296A1 (en) 2017-09-08 2019-03-14 Genentech, Inc. DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
CZ303815B6 (cs) 2000-07-19 2013-05-15 Warner-Lambert Company Derivát O-substituovaného esteru 4-jodfenylaminobenzhydroxamové kyseliny a farmaceutický prípravek s jeho obsahem
CN1290846C (zh) * 2001-04-27 2006-12-20 卫材株式会社 吡唑并[1,5－a]吡啶化合物及其药物
PA8569201A1 (es) 2002-03-13 2004-05-21 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimimidazole derivatives as mek inhibitors"
SI2130537T1 (sl) 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
JP3764440B2 (ja) * 2002-05-24 2006-04-05 日東電工株式会社 光学フィルムの製造方法
GB0226724D0 (en) * 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
ATE443063T1 (de) * 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen

Similar Documents

Publication Publication Date Title
JP2011507888A5 (enExample)
JP2011526926A5 (enExample)
JP2009507909A5 (enExample)
JP2011526924A5 (enExample)
JP2015511638A5 (enExample)
JP2011529073A5 (enExample)
JP2007505877A5 (enExample)
JP2013010792A5 (enExample)
EA036446B1 (ru) Соединения и композиции для подавления активности shp2
JP2005519932A5 (enExample)
JP2008526999A5 (enExample)
JP2008195730A5 (enExample)
JP2016506387A5 (enExample)
RU2008142841A (ru) СОЕДИНЕНИЯ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЙ ИМИДАЗО-[1, 2-b]-ПИРИДАЗИНА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ ГАМКА РЕЦЕПТОРОВ
JP2005511531A5 (enExample)
JP2010509356A5 (enExample)
JP2012041365A5 (enExample)
JP2008509187A5 (enExample)
JP2009526831A5 (enExample)
JP2011507896A5 (enExample)
JP2007515476A5 (enExample)
JP2011505356A5 (enExample)
CN1638739A (zh) 治疗成瘾性障碍的化合物
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
CA2728098A1 (en) Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor